The global severe asthma drugs market size is estimated to reach USD 26.05 Billion in 2025. It is forecasted to reach a valuation of USD 39.95 Billion by 2032, by exhibiting a CAGR of 6.3% throughout the forecast period (2025-2032).
Severe asthma and its types are persistent in individuals despite the intake of high-dose corticosteroids and are distinct from poorly controlled asthma. The market is anticipated to scale over the forecast period owing to a surge in air pollution levels caused by rapid industrialization.
The use of monoclonal antibodies (mAb) for inhibiting pathways that drive inflammation is likely to drive the market growth. But their high prices can limit the market growth.
Key Market Insights
The severe asthma drugs market is expected to be marked by non-invasive biomarkers for asthma diagnosis and clinical trials of novel mAbs.
The full report is now available for purchase: https://www.coherentmi.com/industry-reports/severe-asthma-drugs-market
Severe Asthma Drugs Market Report Coverage
|
Report Coverage |
Details |
|
Market Revenue in 2025 |
USD 26.05 Billion |
|
Estimated Value by 2032 |
USD 39.95 Billion |
|
Growth Rate |
6.3% |
|
Historical Data |
2020–2024 |
|
Forecast Period |
2025–2032 |
|
Forecast Units |
Value (USD billion) |
|
Report Coverage |
Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
|
Segments Covered |
|
|
Geographies Covered |
North America (U.S. and Canada), Latin America (Brazil, Argentina, Mexico, and Rest of Latin America), Europe (Italy, Spain, U.K., Germany, France, Russia, and Rest of Europe), Asia Pacific (China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific), Middle East (GCC Countries, Israel, and Rest of Middle East), and Africa (South Africa, North Africa, and Central Africa) |
|
Growth Drivers |
|
|
Opportunities |
|
|
Trends |
|
|
Restraints & Challenges |
|
Market Dynamics
The leaps in lung health research for the treatment of respiratory diseases can have a positive impact on the severe asthma drugs market. The repurposing of benralizumab, also known as Fasenra, administered at the point of exacerbation, can be used in the management of the disease. A study published in January 2025 in the Lancet Respiratory Medicine, outlined its advantage over steroids in the treatment of lung inflammation.
Clinical trials on bronchodilator delivery devices and drugs are likely to pave the way for increased funding in the market. The results of a recent study presented at the European Academy of Paediatrics highlighted the promise of the SOBIstat-F device, a delivery mask. The mask proved to reduce the hospitalization rates among candidates and better oxygenation.
Market Opportunity
Bronchodilator Delivery Mask to Improve Outcomes in Pediatric Patients
As per a recent report by the Centers for Disease Control & Prevention (CDC), children accounted for 6.5% of asthma globally. The need for preventive measures for the management of severe asthma among children and alleviating their burden can be a lucrative opportunity for the severe asthma drugs market.
A combination therapy comprising formoterol and budesonide can relieve inflammation in children between the ages of 5-15. The clinical trial was led by the Medical Research Institute of New Zealand (MRINZ), in collaboration with the University of Auckland, Imperial College London, University of Otago, and Starship Children’s Hospital.
Market Challenges
Limited Insurance Coverage
The limited insurance coverage for drugs used in the treatment of severe asthma can significantly limit the market growth. This is despite the strong demand for biologics. For instance, BlueCross BlueShield rolled out a new policy on February 04, 2025, limiting access to asthma infusion treatment within office premises. The drugs — Tezspire, Fasenra, Nucala, and Xolair, can only be administered at home in the U.S. states of Oklahoma, New Mexico, Montana, Texas, and Illinois. This can culminate in a drop in patient adherence to medications and negatively affect the severe asthma drugs market.
Analyst’s View
Recent Developments
Kinaset Therapeutics gained clearance from the U.S. Food and Drug Administration for frevecitinib, an inhaled dry powder, on January 29, 2025.
Competitor Insights
Market Segmentation
Regional Insights
Related Reports :